×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SNY – sanofi - american depositary shares (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SNY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
05:00 am
sny
Press Release: Sanofi completes acquisition of Vicebio
Low
Report
Press Release: Sanofi completes acquisition of Vicebio
12/3
07:07 am
sny
Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
11/28
02:42 am
sny
Deutsche Bank Maintains a Buy Rating on Sanofi (SNY) [Yahoo! Finance]
Low
Report
Deutsche Bank Maintains a Buy Rating on Sanofi (SNY) [Yahoo! Finance]
11/26
11:17 am
sny
Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation [Yahoo! Finance]
Low
Report
Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation [Yahoo! Finance]
11/26
08:28 am
sny
AI won't cure cancer, says Sanofi CEO [CNBC]
Neutral
Report
AI won't cure cancer, says Sanofi CEO [CNBC]
11/25
04:34 am
sny
Sanofi (ENXTPA:SAN) Valuation: Is the Recent Share Price Pullback a Long-Term Opportunity? [Yahoo! Finance]
Low
Report
Sanofi (ENXTPA:SAN) Valuation: Is the Recent Share Price Pullback a Long-Term Opportunity? [Yahoo! Finance]
11/25
02:20 am
sny
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria [Yahoo! Finance]
Low
Report
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria [Yahoo! Finance]
11/25
01:00 am
sny
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Low
Report
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:35 pm
sny
Form SCHEDULE 13G/A Sanofi Filed by: Amundi
Low
Report
Form SCHEDULE 13G/A Sanofi Filed by: Amundi
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Sanofi, Regeneron begin testing arthritis drug as coronavirus treatment [Reuters (UK)]
8.5%
3/13 Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use [Canadian Business Journal (Canada)] 8.2%
12/9 Sanofi ends research in diabetes, narrows units to spur profits [Reuters] 7.0%
3/17 Sanofi SA (NYSE: SNY) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. 6.5%
4/24 Sanofi confirms targets, strong demand for pain killers lifts first quarter [CNBC] 6.1%
6/6 Runners-Up From Our Sixth Annual Student Editorial Contest [The New York Times] 6.0%
3/3 FDA Approves Sanofi's Multiple Myeloma Drug [The Motley Fool] 5.9%
2/28 UPDATE 1-Sanofi to pay $11.9 mln to resolve U.S. drug charity kickback probe [Reuters] 5.4%
2/6 Sanofi delivers strong 2019 business EPS growth of 6.8% at CER 4.2%
4/13 Reasons for hope: the drugs, tests and tactics that may conquer coronavirus [Reuters] 3.6%
3/13 Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use [Canadian Business Journal (Canada)] 8.2%
12/9 Sanofi ends research in diabetes, narrows units to spur profits [Reuters] 7.0%
3/17 Sanofi SA (NYSE: SNY) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. 6.5%
4/24 Sanofi confirms targets, strong demand for pain killers lifts first quarter [CNBC] 6.1%
6/6 Runners-Up From Our Sixth Annual Student Editorial Contest [The New York Times] 6.0%
3/3 FDA Approves Sanofi's Multiple Myeloma Drug [The Motley Fool] 5.9%
2/28 UPDATE 1-Sanofi to pay $11.9 mln to resolve U.S. drug charity kickback probe [Reuters] 5.4%
2/6 Sanofi delivers strong 2019 business EPS growth of 6.8% at CER 4.2%
4/13 Reasons for hope: the drugs, tests and tactics that may conquer coronavirus [Reuters] 3.6%
TOP News Decliners
3/17
Here are some of the existing drugs that may be repurposed to treat coronavirus [MSNBC.com]
-7.7%
3/6 Algernon Announces Availability of its NP-120 Ifenprodil Drug for Compassionate Use for Coronavirus [Canadian Business Journal (Canada)] -6.6%
3/16 Regeneron Is A Phenomenal Growth Story; Buying The Current Dip Could Be A Wise Move [Seeking Alpha] -6.5%
4/14 GlaxoSmithKline CEO calls coronavirus vaccine partnership with Sanofi 'unprecedented collaboration' [CNBC] -4.8%
4/29 GlaxoSmithKline plc (GSK) Q1 2020 Earnings Call Transcript [The Motley Fool] -4.5%
10/31 Sanofi Q3 well on track -4.0%
1/30 Human Insulin Is Available For As Little As $24.88 - But It’s Not For Everyone [Forbes] -3.4%
4/6 Sanofi upsizes debt offerings to €4B; shares up 2% [Seeking Alpha] -3.3%
3/2 Sanofi Pasteur researcher warns against overconfidence with coronavirus vaccine development [CNBC] -3.1%
3/5 Form IRANNOTICE Sanofi -3.0%
3/6 Algernon Announces Availability of its NP-120 Ifenprodil Drug for Compassionate Use for Coronavirus [Canadian Business Journal (Canada)] -6.6%
3/16 Regeneron Is A Phenomenal Growth Story; Buying The Current Dip Could Be A Wise Move [Seeking Alpha] -6.5%
4/14 GlaxoSmithKline CEO calls coronavirus vaccine partnership with Sanofi 'unprecedented collaboration' [CNBC] -4.8%
4/29 GlaxoSmithKline plc (GSK) Q1 2020 Earnings Call Transcript [The Motley Fool] -4.5%
10/31 Sanofi Q3 well on track -4.0%
1/30 Human Insulin Is Available For As Little As $24.88 - But It’s Not For Everyone [Forbes] -3.4%
4/6 Sanofi upsizes debt offerings to €4B; shares up 2% [Seeking Alpha] -3.3%
3/2 Sanofi Pasteur researcher warns against overconfidence with coronavirus vaccine development [CNBC] -3.1%
3/5 Form IRANNOTICE Sanofi -3.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: